HC Wainwright Has Pessimistic Outlook of ASMB Q4 Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – HC Wainwright reduced their Q4 2027 earnings per share estimates for Assembly Biosciences in a research note issued on Tuesday, August 18th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings of $1.63 per share for the quarter, down from their prior forecast of $1.66. HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is $1.90 per share.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.52. The company had revenue of $13.37 million during the quarter, compared to analyst estimates of $8.60 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%.

ASMB has been the subject of a number of other reports. Wall Street Zen downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Mizuho set a $45.00 target price on Assembly Biosciences and gave the stock an “outperform” rating in a research note on Monday, June 15th. Finally, Guggenheim reiterated a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a research report on Thursday, May 28th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Assembly Biosciences Price Performance

NASDAQ:ASMB opened at $32.13 on Wednesday. The company’s fifty day moving average price is $26.43 and its 200-day moving average price is $27.44. Assembly Biosciences has a 1-year low of $20.23 and a 1-year high of $39.71. The firm has a market capitalization of $510.64 million, a P/E ratio of 31.50 and a beta of 1.10.

Institutional Investors Weigh In On Assembly Biosciences

Several large investors have recently bought and sold shares of ASMB. RA Capital Management L.P. acquired a new position in shares of Assembly Biosciences during the third quarter valued at approximately $26,122,000. Janus Henderson Group PLC raised its stake in Assembly Biosciences by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock valued at $23,479,000 after purchasing an additional 11,384 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new position in Assembly Biosciences in the 4th quarter valued at $22,625,000. Vanguard Group Inc. boosted its stake in Assembly Biosciences by 97.8% during the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after purchasing an additional 248,287 shares during the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in shares of Assembly Biosciences during the third quarter worth $6,425,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.